Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

tremtelectogene empogeditemcel

A preparation of allogeneic, human leukocyte antigen (HLA) matched, cluster of differentiation 34 (CD34)-positive human hematopoietic stem and progenitor cells (HSPCs) that are ex-vivo gene-edited with the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 nuclease complex to remove the cluster of differentiation 33 (CD33) antigen, that can potentially be used to improve hematopoietic recovery after hematopoietic cell transplantation (HCT) and CD33-targeting chemotherapy. Upon administration, tremtelectogene empogeditemcel increases and restores the number of HSPCs, which may prevent or decrease infection and other complications of HCT and chemotherapy-induced neutropenia (CIN). The removal of CD33 protects VOR33 from the cytotoxic effects of CD33-targeted agents administered after HCT.
Synonym:allogeneic CRISPR/Cas9-edited CD33-depleted CD34-positive hematopoietic stem and progenitor cells VOR33
allogeneic CRISPR/Cas9-edited CD33-depleted CD34-positive HSCs VOR33
allogeneic CRISPR/Cas9-edited CD33-depleted CD34-positive HSPCs VOR33
eHSCs VOR33
Trem-cel
Code name:VOR 33
VOR-33
VOR33
Search NCI's Drug Dictionary